

SUMMARY OF SAFETY AND EFFECTIVENESS

Assigned 510(k) Number

AUG - 1 2011

The assigned 510(k) number is k101572

Sponsor Name and Address

Siemens Healthcare Diagnostics Inc.
5210 Pacific Concourse Drive
Los Angeles, CA
90045-6900
(310) 645-8200

Contact

Clare Santulli
Sr.Regulatory Affairs Specialist
(914) 524-2701
(914) 524-3579 fax
clare.santulli@siemens.com

Device Name

Trade name:	IMMULITE® 2000 3gAllergy™ Specific IgE Assay
Classification:	Class II
Classification Names:	Radioallergosorbent (RAST) Immunological Test System
Regulation Number:	866.5750
Product Code:	DHB
Catalog Numbers:	L2KUN6 (600 tests)

Description of Device

IMMULITE® 2000 3gAllergy™ Specific IgE is a solid-phase, two-step, chemiluminescent immunoassay that exploits liquid phase kinetics in a bead format.^{1,2} (U.S. Patent No. 4,778,751) It represents a significant advance over conventional methods relying on allergens attached to a solid-phase support, such as a paper disk.

The allergens are covalently bound to a soluble polymer/co-polymer matrix, which in turn is labeled with a ligand. The use of an amino acid co-polymer amplifies the amount of allergen that the matrix can support.

Incubation Cycles: 2 × 30 minutes.

¹ El Shami AS, Alaba O. Liquid-phase *in vitro* allergen-specific IgE assay with *in situ* immobilization. Adv Biosci 1989;74:191-201.

² Alaba O, El Shami AS. Evaluation of non-specific IgE binding: comparison of two *in vitro* allergen assays. Adv Biosci 1989;74:203-14.

Indications for Use

For *in vitro* diagnostic use with the IMMULITE® 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders. The test results are to be used in conjunction with clinical findings and other laboratory tests.

Establishment Information

IMMULITE® 2000 3gAllergy Specific IgE assay is manufactured by Siemens Healthcare Diagnostics Inc. at the following locations:

Siemens Healthcare Diagnostics Inc.
5210 Pacific Concourse Drive
Los Angeles, CA 90045-6900
FDA Establishment #: 3005250747

Predicate

The purpose of this 510(k) submission is for clearance of nine additional specific allergens, named in the table below, to be used with the IMMULITE® 2000 3gAllergy™ Specific IgE on the IMMULITE® 2000 analyzer.

1	F86 Parsley
2	F93 Cacao
3	F234 Vanilla
4	F253 Pine Nut
5	F269 Basil
6	F283 Oregano

FDA clearance was previously obtained for the assay kit and 196 specific allergens and allergen panels (K013134, K021206, K013135 and K021208).

Please note that the FDA clearances indicated above were in the name of Diagnostic Products Corporation which was acquired by Siemens Medical Solutions Diagnostics in July 2006. Siemens Medical Solutions Diagnostics was renamed Siemens Healthcare Diagnostics Inc. on January 1, 2008.

Precision

Precision studies were performed in accordance with Clinical Laboratory Standard Institute (CLSI) guidance: *Evaluation of Precision Performance of Quantitative Methods; Approved Guideline-Second Edition*. CLSI document EP5-A2 (ISBN 1-56238-542-9). CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004, assaying two aliquots of each test

sample in two runs per day on 20 different days (Positives 1-3). Additional studies for Positives 4 were done assaying two aliquots of each test sample in two runs per day on 10 different days. Analysis of variance was used to estimate the within-run and total precision.

Three allergen lots were tested using three positive samples and one negative sample. Intra-assay and inter-assay precision for the positive samples were evaluated by calculating the kU/L dose percent coefficients of variation (%CV) for each positive sample. Non-specific binding (NSB) was monitored by testing the negative control sample.

Representative precision claims for each allergen tested are presented below:

Allergen Precision Claims*

Sample	Within-Run			Total	
	Mean kU/L	SD kU/L	CV %	SD kU/L	CV %
Allergen = Basil, Lot 115					
Positive #1	0.318	0.014	4.49	0.020	6.34
Positive #2	0.776	0.047	6.09	0.051	6.55
Positive #3	2.537	0.133	5.23	0.202	7.94
Positive #4	2.13	0.089	4.17	0.127	5.95
Allergen =Cacao, Lot 101					
Positive #1	0.519	0.019	3.56	0.023	4.43
Positive #2	1.370	0.040	2.89	0.073	5.32
Positive #3	17.327	0.788	4.55	0.939	5.42
Allergen = Oregano, Lot 114					
Positive #1	0.283	0.014	4.94	0.016	5.58
Positive #2	0.824	0.025	3.06	0.050	6.09
Positive #3	0.474	0.017	3.52	0.023	4.80
Positive #4	2.43	0.074	3.04	0.121	4.97
Allergen = Parsley, Lot 117					
Positive #1	0.374	0.017	4.60	0.021	5.70
Positive #2	0.909	0.032	3.49	0.033	3.65
Positive #3	3.658	0.121	3.31	0.168	4.58
Allergen =Pine Nut, Lot 112					
Positive #1	0.639	0.030	4.71	0.031	4.90
Positive #2	0.885	0.036	4.07	0.043	4.82
Positive #3	1.421	0.065	4.56	0.085	5.95
Positive #4	5.58	0.476	8.54	0.518	9.29
Allergen = Vanilla, Lot 115					
Positive #1	0.614	0.027	4.33	0.040	6.53
Positive #2	3.848	0.095	2.48	0.165	4.29
Positive #3	8.317	0.245	2.95	0.321	3.86

data are representative of one lot on one instrument

Linearity

For each allergen, two samples were diluted in 2-fold serial dilutions to 5 levels. The undiluted (neat) and diluted samples were tested with the specific allergen to demonstrate linearity at concentrations within the assay limits. Regression statistics for each allergen comparing observed to expected data are presented below.

Linearity

Allergen	Regression Equation	N	95% CI	95% CI
Parsley	$Y = 1.002X + 0.0223$	12	0.969–1.036	-0.0483-0.093
Cacao	$Y = 1.011X + 0.0444$	10	0.980–1.0242	-0.0659-0.155
Vanilla	$Y = 0.975X + 0.1233$	11	0.890–1.060	0.0321-0.2146
Pine Nut	$Y = 0.996X - 0.0099$	10	0.941–1.052	-0.0934-0.074
Basil	$Y = 0.974X + 0.1141$	10	0.885–1.063	0.0227-0.2055
Oregano	$Y = 0.966X + 0.0686$	8	0.870–1.062	0.0005-0.1368

Specificity (Inhibition) Studies

Specificity of each allergen was verified through competitive inhibition testing using a single serum sample or pool of sera. A negative sample was used to measure the background response.

To initiate the inhibition experiment, 70 μ L of undiluted and 3-4 levels of 5-fold serially diluted inhibitor extract were mixed with 250 μ L of sample or pool to achieve final inhibitor concentrations of 1093.75, 218.75, 43.75, 8.75, 1.75, 0.35 μ g/mL. This mixture was incubated at room temperature (15-28 $^{\circ}$ C) for 1 hour allowing the immunological reaction to occur. Each sample mixture containing the inhibitor extract and the appropriate controls was assayed with 1 lot of each allergen. The percent (%) inhibition was calculated according to the following formula:

$$\frac{(\text{Response of pos. control (pos. sample - neg. sample)} - \text{sample response with inhibitor extract})}{(\text{Response of pos. control (pos. sample - neg. sample)})} \times 100$$

The inhibition study demonstrated that the allergens tested are inhibited by the relevant inhibitor extract in a concentration dependent fashion. Also, the target % inhibition of 50% was met. These results indicate specificity of the Basil, Cacao, Oregano, Parsley, Pine Nut, and Vanilla allergens.

Inhibition Using Negative Controls

Additional inhibition studies were conducted to show that the specific allergens are not cross-reacting to the unrelated allergens. Procedures were followed according to CLSI ILA20-A, Appendix-D. Testing was performed using one positive sample with three unrelated allergen extracts at 1 mg/ml. A negative sample was used to measure the background response. Results on the following specific allergen(s) were below 19.3% for Basil, Cacao, Oregano, Parsley, Pine Nut, and Vanilla

Clinical Performance Studies

Clinical performance of Basil, Cacao, Oregano, Parsley, Pine Nut, and Vanilla allergens was demonstrated by testing samples from non-atopic individuals and samples from atopic patients with case histories of suspected clinical reactions to the specific allergen or allergy group in the IMMULITE® 2000 3gAllergy Specific IgE assay and comparing results to accompanying clinical information:

Data summary agreement of the IMMULITE® 2000 3gAllergy results to clinical data is presented in the table below.

IMMULITE® 2000	Clinical Data				
	Clinical	Normal	Total		
Positive	116	0	116		
Negative	112	600	712		
Total	228	600	828		
	50.9%	100.0%	86.5%		
	Sensitivity	Specificity	Agreement		
Lower Conf	44%	100%	84%		
Upper Conf	57%	100%	89%		
Allergens included: Basil, Cacao, Oregano, Parsley, Pine Nut, and Vanilla.					

IMMULITE® 2000 3gAllergy assay results for all allergens compare well with clinical documentation of presence or absence of signs, symptoms and other diagnostic evidence of allergen sensitivity.

Conclusions for all Studies

Allergens including Basil, Cacao, Oregano, Parsley, Pine Nut, and Vanilla for use with the IMMULITE® 2000 3gAllergy Specific IgE assay demonstrate acceptable analytical performance including precision, linearity and specificity. IMMULITE® 2000 assay results compare well with clinical documentation of presence or absence of signs, symptoms and other diagnostic evidence of allergen sensitivity. Substantial equivalence was demonstrated

to clinical data, supporting the following intended use of the IMMULITE® 2000 3gAllergys Specific IgE assay and the 6 previously listed allergens:

For *in vitro* diagnostic use with the IMMULITE® 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders. The test results are to be used in conjunction with clinical findings and other laboratory tests.



Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Siemens Healthcare Diagnostics, Inc
c/o Ms. Clare Santulli
Sr. Regulatory Technical Specialist
511 Benedict Avenue
Tarrytown, NY 10591

AUG 01 2011

Re: k101572

Trade/Device Name: IMMULITE® 2000 3gAllergy™ Specific IgE Assay Kit
Regulation Number: 21 CFR §866.5750
Regulation Name: Radioallergosorbent (RAST) Immunological Test System
Regulatory Class: Class II
Product Codes: DHB
Dated: July 1, 2011
Received: July 5, 2011

Dear Ms. Santulli:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Maria M. Chan", is written over a horizontal line.

Maria M. Chan, Ph.D.
Director
Division of Immunology and Hematology Devices
Office of *In Vitro* Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indication for Use

510(k) Number (if known) k101572

Device Name: IMMULITE 3gAllergy™ Specific IgE Assay

Indication For Use:

For *in vitro* diagnostic use with the IMMULITE 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders. The test results are to be used in conjunction with clinical findings and other laboratory tests.

Prescription Use ✓
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K101572